Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.30 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118871 | 0.90 | DHFR (0.34) | TP53ABL1F2RL3FLT3SYK | |
| SCHEMBL1118648 | 0.84 | TNK2 (0.40) | TNK2ABL1ACP1F2RL3FLT3 | |
| SCHEMBL1118861 | 0.80 | RXFP1 (0.38) | TP53RXFP1ABL1MAPTFLT3 | |
| SCHEMBL458489 | 0.77 | ALDH1A1 (0.37) | ABL1MAPTFLT3SYKAURKB | |
| SCHEMBL1119821 | 0.75 | ATR (0.41) | ABL1MAPTALDH1A1 | |
| SCHEMBL113156 | 0.75 | POLB (0.41) | ABL1MAPTPOLBALDH1A1 | |
| SCHEMBL1118890 | 0.74 | DHFR (0.40) | TNK2ACP1F2RL3FLT3MCL1 | |
| SCHEMBL20699326 | 0.69 | RXRA (0.41) | TP53RXFP1MAPTPOLBWNK1 | |
| SCHEMBL30161733 | 0.69 | RXRA (0.41) | TP53RXFP1MAPTPOLBWNK1 | |
| SCHEMBL16021495 | 0.68 | HTT (0.44) | MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| EP-2280946-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | Glaxo Group Limited (GB) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | CDK3, CDK13, MAP3K13 | TP53 612/4885TNK2 68/4885RXFP1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.